Navigation Links
pFB-ERV: Retroviral Delivery of the Ecdysone Receptor Proteins


Faster, easier screening for difficult transfections when using the complete control kit

Peter Vaillancourt Katherine A. Felts
Stratagene

We describe the vector pFB-ERV, an MMLV-based replication-defective retroviral vector for delivery of the ecdysone receptor proteins RXR and VgEcR. In stable cell lines infected with an estimated single copy of the receptor cassette, induction ratios of greater than 200-fold are attainable in transient reporter transfection assays. The neo-resistance marker is expressed as the third open reading frame (ORF) in a tricistronic CMV expression cassette (the two receptors comprise the first and second ORFs); cell lines harboring single-copy integrants are resistant to as high as 1 mg/ml G418. The CMV promoter ### is flanked by unique restriction sites and, thus, can be replaced with a cell-type specific promoter of interest.

DNA vector-based systems that allow precise control of gene expression in vivo have become invaluable for the study of gene function in a variety of organisms, particularly when applied to the study of developmental and other biological processes for which the timing or dosage of gene expression is critical to gene function. Such systems have also been successfully used to overexpress toxic or disease-causing genes, to induce gene targeting, and to express antisense RNA. Inducible systems are currently being used by pharmaceutical companies to facilitate screening for inhibitors of clinically relevant biological pathways, and potential applications for gene therapy are being explored.1

Stratagenes complete control inducible system is based on the insect molting hormone ecdysone, which can stimulate transcriptional activation in mammalian cells harboring the ecdysone receptor protein from Drosophila melanogaster.2,3 The ecdysone-inducible system has a number of advantages over alternative systems. Firstly, the lipophilic nature and short in vivo half-life of the ecdysone analog ponasterone A (ponA) allow efficient penetrance into all tissues including brain, resulting in rapid and potent inductions and rapid clearance. Secondly, ecdysteroids are not known, nor are they expected, to affect mammalian physiology in any measurable way. Thirdly, the heterodimeric ponA responsive receptor and receptor DNA recognition element have been genetically altered such that trans-activation of endogenous genes by the ecdysone receptor, or of the ponA-responsive expression cassette by endogenuos transcription factors, is extremely unlikely.

In addition, it has been found that in the absence of inducer the heterodimer remains bound at the promoter in a complex with corepressors and histone deacetylase, and is, thus, tightly repressed until ligand binding, at which time high-level transcriptional activation occurs (i.e., the heterodimer is converted from a tight repressor to a trans-activator). Using the Complete Control plasmid-based system, induction ratios of greater than 1,000-fold have been achieved in both transient transfections and in stable cell lines.3

Using plasmid-based vectors for controlled gene expression is limiting because many cell types that are of academic, industrial, or clinical interest are difficult or virtually impossible to transfect using current transfection methods. In particular, primary human cell lines and lymphocytes are best transduced using viral delivery systems. The most popular and user-friendly of these are the retroviral vectors.4,5 Infection with retroviruses often yields transduction efficiencies close to 100%, and the proviral copy number can be easily controlled by varying the multiplicity of infection (MOI). This latter feature is particularly important for inducible systems for which low basal expression and high induction ratios are affected by copy number. Hence, viral infection (at an optimal MOI) of the target cell should yield a high frequency of clones capable of mediating desirable expression profiles without exhaustive colony screening.

We describe the vector pFB-ERV, an MMLV-based replication-defective retroviral vector for delivery of the ecdysone receptor proteins RXR and VgEcR.

Vector Description

Fig.1

The vector pFB-ERV contains a tricistronic message transcribed from the CMV promoter (Figure 1). The receptor proteins VgEcR and RXR are expressed from the first and second open reading frames (ORF), respectively,

and the neomycin-resistance gene is expressed from the third ORF. Translation of the RXR and Neo ORFs is mediated by the EMCV-IRES (both IRESs are identical). In this context, G418 selection and maintenance of the expression cassette in stably infected cells ensures that the receptor-encoding mRNA is transcribed. The CMV expression cassette was built into a self-inactivating (SIN) vector backbone,6,7 in which the retroviral promoter within the U3 region of the 3 LTR was deleted. In SIN vectors, viral genomic RNA is expressed from the 5 viral LTR in packaging cells; however, upon infection the virus replicates in such a way that the (inactive) 3 U3 promoter sequences are transferred to the 5 LTR, and the proviral 5 promoter is then inactive in infected cells. The rationale for this construction is the following: The CMV promoter is stronger than the MMLV LTR and is persistently active in a wider range of cell types, and inactivation of the 5 LTR obviates potential interference with the CMV promoter; the CMV promoter can be readily replaced with a cell-type promoter of interest using the unique EcoR I and Fse I sites without concern of ubiquitous read-through from the 5 LTR; spurious activation/transcription of 3-flanking endogenous genes from the promoter within the 3 LTR will not occur in the SIN vector; and inactivation of the proviral LTRs protects against mobilization of proviral pFB-ERV derivatives by endogenous retroviral structural proteins.

Titer Determination

Vector titer was determined by G418-resistant colony formation. Amphotropic virus was produced by transient transfection using the producer line HW293-A (unpublished data), and viral supernatants were used to infect NIH3T3 cells. In Table 1, the titers for both experiments are on the order of 105 colony forming units (cfu)/ml. Even at high dilutions of supernatant (1:103), which likely give rise to single-copy infected cells in accordance with the Poisson kinetics of viral transduction, colonies are resistant to as high as 1 mg/ml G418 without substantial loss of titer, indicating efficient expression of the Neo gene from the third ORF.

Performance of pFB-ERV in Mass Populations of Infected Cells

Fig.2

NIH3T3 cells were infected with various dilutions of viral supernatant, and one day following infection the cells were transfected with the ecdysone-inducible reporter vector pEGSH-luc. The following day, cells were induced for 20 hours with ponA, then assayed for luciferase activity. In Figure 2 (at an MOI of 1.0), a strong induction is achieved, which is reproducible in separate infected populations.

Analysis of Clonal Isolates of Individual Cells Infected with pFB-ERV

Fig.3

NIH3T3 cells were infected with pFB-ERV supernatants and selected with 600 g/ml G418. Resistant colonies were picked and expanded. In an initial screen, 24 colonies were transfected with reporter vector, and induced with 10 M ponA or an equivalent volume of vehicle. All 24 of the infected lines showed a pon A- dependent induction to some degree (Figure 3). One clone, A610-20 (clone #20, Figure 3) gave an induction of greater than 200-fold in the initial screen. A retest of this cell line gave an induction of approximately 250-fold (Figure 3B ). This clone was produced by infection at an MOI of 0.1, and, therefore, the colony theoretically has a single integrated copy of the receptor expression cassette.

Conclusions

The 200-fold induction seen by transient reporter transfection of the A610-20 receptor line is likely to be an under-representation of the induction profile to be expected in double-stable lines made by selecting stably integrated inducible vectors. This is due to the tight repression that occurs for chromosomally integrated ecdysone-responsive promoters, compared with the relatively high background normally seen in transient transfection assays in which the reporter is free in the nucleus. The stable cell line ER-CHO, which was made using the receptor-expressing plasmid pERV3, shows at best 50-fold induction ratios by transient reporter transfection but the derivative double-stable line consistently gives induction ratios of 700- greater than 1,000-fold.3 Accordingly, we expect that the A610-20 receptor line will give rise to double-stable lines with induction ratios well in excess of 1,000-fold.

Retroviral delivery of the ecdysone receptors should significantly decrease the time and labor required to screen for stable clones that express the receptors at optimal levels, particularly for cell types that are normally difficult to transfect. However, for difficult-to-transfect cell types, delivery of the receptors with the pFB-ERV virus only solves half the problem. Currently, the ecdysone-inducible vectors need to be delivered by transfection. At this writing, several ecdysone-inducible retroviral constructions are being evaluated for efficient delivery of inducible expression cassettes that allow fine control of expression and high-level induction of the gene of interest. The use of a two-virus system for delivery of the edysone-inducible expression system will further expand the range of cell types in which ecdysone-regulated expression can be achieved, while further reducing the time, cost, and labor of screening for clones that show optimal expression characteristics.

REFERENCES

  1. Schockett, P.E. and Schatz, D.G. (1996) Proc. Natl. Acad. Sci. 93: 5173-5176.

  2. No, D., et. al. (1996) Proc. Natl. Acad. Sci. 93: 3346-3351.

  3. Wyborski, D. and Vaillancourt, P. (1999) Strategies in Mol. Biol. 12(1): 1-4.

  4. Miller, A.D. (1997) In Retroviruses (Eds., Coffin, J.M., Hughes, S.H., and Varmus, H.E.) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. pp. 437-473.

  5. Felts, K.A., et. al. (1999) Strategies in Molec. Biol. 12(2): 74-77.

  6. Yu, S.-F., et. al. (1986) Proc. Natl. Acad. Sci. 83: 3194-3198.

  7. Yee, J.-K. (1987) Proc. Natl. Acad. Sci. 84: 5197-5201.


'"/>

Source:


Page: All 1 2 3 4 5 6

Related biology technology :

1. Functional Cloning Using ViraPort Retroviral cDNA Expression Libraries
2. High-Titer Retroviral Vectors for Gene Delivery
3. A New Way to Assess siRNA Delivery Efficiency
4. Efficient Delivery of siRNAs to Human Primary Cells: Electroporation vs. Chemical Transfection
5. Enhanced siRNA Delivery and Long-term Gene Silencing
6. High Throughput siRNA Delivery In Vitro: From Cell Lines to Primary Cells
7. Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice
8. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
9. Detecting Gastrin-Releasing Peptide Receptor by in situ PCR on Archived Tissue
10. Gene-Specific Primers for NMDA Receptor Subunits
11. TKB1 Cells Identify Receptor Tyrosine Kinase Interacting Proteins
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: pFB ERV Retroviral Delivery the Ecdysone Receptor Proteins

(Date:10/22/2014)... YORK , Oct. 22, 2014 New ... in the in vitro diagnostic (IVD) test industry, especially ... Information. The healthcare market researcher listed more than 25 testing ... could be the future of IVD products. Kalorama details the ... The Worldwide Market for In Vitro Diagnostic Tests ...
(Date:10/22/2014)... October 21, 2014 The North American ... market North America with analysis and forecast of revenue. ... and is expected to reach $623.6 million by 2018, ... , Browse through the TOC of the North American ... the in-depth analysis provided. This also provides a glimpse ...
(Date:10/22/2014)... 22, 2014 Currently offering a ... & D Weighing, Rice Lake, and Ohaus, Pipette.com ... . The Sartorius CPA Semi-Micro Balance is ideal ... precise, and user-friendly laboratory balance. , Sartorius is ... their laboratory balances are well known for their ...
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
Breaking Biology Technology:Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... 22 Insmed Inc. (Nasdaq:,INSM), a developer of follow-on ... the recently disclosed temporary suspension,of NASDAQ,s minimum bid closing ... the Company now has until March 20, 2009 to ... a closing bid price of $1.00 or more for ...
... NicOx,S.A. (Euronext Paris: COX) today reported financial results for the nine,months ... quarter of 2008:, - Positive top-line results from the 302 ... co-primary efficacy endpoints at week-13 (p naproxcinod 750 ... non-inferiority to naproxen 500 mg bid at week-13 and 26. ...
... to Show Encouraging and Durable Anti-Tumor Activity and ... Dose Escalation Continues -, - Results Presented at ... Targets and ... MDVN ) today announced the presentation of new data from an,ongoing Phase ...
Cached Biology Technology:NASDAQ's Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmed's Compliance Date to March 20, 2009 2NicOx Reports Results for the First Three Quarters of 2008 2NicOx Reports Results for the First Three Quarters of 2008 3NicOx Reports Results for the First Three Quarters of 2008 4NicOx Reports Results for the First Three Quarters of 2008 5NicOx Reports Results for the First Three Quarters of 2008 6NicOx Reports Results for the First Three Quarters of 2008 7NicOx Reports Results for the First Three Quarters of 2008 8NicOx Reports Results for the First Three Quarters of 2008 9NicOx Reports Results for the First Three Quarters of 2008 10Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 2Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 3Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 4
(Date:10/22/2014)... DENVER , Oct. 20, 2014  Leading identity ... years time half of the world,s population will have ... in Europe . Asia ... dominate the market accounting for more than 60% of ... Acuity,s report  -- "The Global National ...
(Date:10/18/2014)... patients with undiagnosed, suspected genetic conditions, a certain type ... molecular diagnostic yield than traditional molecular diagnostic methods, according ... study is being released to coincide with the American ... which sequences the protein­coding region of the genome (the ... a cell or organism), has been rapidly applied in ...
(Date:10/16/2014)... human body. Battles are won, lost or sometimes ... stalemate—known as tumor dormancy—can last up to 25 ... is poorly understood. , A new computational ... a Professor of Chemistry at Princeton University, may ... the switch to a malignant state. Published today ...
Breaking Biology News(10 mins):Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Modeling tumor dormancy 2
... Langone Medical Center,s Departments of Orthopaedic Surgery and Radiology ... detect subtle changes in joint cartilage microstructure and ... of early osteoarthritis (OA). By using these techniques during ... the management of the disease from eventual joint reconstruction ...
... Texas A&M Institute of Renewable Natural Resources have discovered fresh ... in Texas, according to a research associate with the institute. ... single individual of false spike "Quadrula mitchelli" with tissue still ... recently alive in the San Saba River ...
... SAN FRANCISCO, CAAugust 14, 2011Scientists at the Gladstone Institutes ... proteins that, when out of balance, can prevent the normal ... be important in some types of cancer. "The news, ... Nature Cell Biology , adds to the understanding of the ...
Cached Biology News:NYU Langone experts find MRI techniques can detect early osteoarthritis 2Researchers discover freshwater mussel species thought to be extinct 2Researchers discover freshwater mussel species thought to be extinct 3Researchers discover freshwater mussel species thought to be extinct 4Gladstone scientists offer new insight into the regulation of stem cells and cancer cells 2Gladstone scientists offer new insight into the regulation of stem cells and cancer cells 3
... The T2-04 is an ultra-compact pump available ... (T2-04 TH) and ideal for use in portable ... 7 slpm, this pump works well in environments ... weight, and compact size are critical., Offers ...
XA7 B6...
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
... The MEGAscript RNAi Kit ... of large mass amounts of ... in non-mammalian systems. The MEGAscript ... Ambions patented high-yield transcription technol-ogy ...
Biology Products: